Barclays’s Editas Medicine EDIT Stock Holding History

Barclays’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,900	Closed	-$68K	–	7183
2018 Q2	$68K	Buy	+1,900	New	+$67.3K	﹤0.01%	5471

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays's EDIT Position: Q1 2026 in Review

Barclays reduced its Editas Medicine (EDIT) stake by 47% in Q1 2026, selling an estimated $277K and leaving 145,602 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #3371.

Barclays first reported a position in EDIT in Q1 2016 and has held it in 40 quarters since. The position peaked at $4.39M in Q1 2021. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

Barclays held 145,602 shares of Editas Medicine worth $360K as of Q1 2026.
Barclays sold 130,660 Editas Medicine shares in Q1 2026, an estimated $277K.
Editas Medicine made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3371 holding.
Barclays first reported a position in Editas Medicine in Q1 2016 and has held it in 40 quarters since.
Barclays's Editas Medicine position peaked at $4.39M in Q1 2021.
207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.